{"preliminary_commentary":{"by_channel":{"x_thread":55,"youtube":8,"podcast":1,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03256981\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[],"indication":"oligoprogressive oncogene-addicted NSCLC","name":"HALT","nct_id":"NCT03256981","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=halt-nct03256981. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"HALT","arms":[{"description":"Patients will continue to receive background TKI treatment as prior to trial entry.\n\nSimultaneous administration (SBRT \\& TKI) or break in TKI during SBRT will be by centre preference and determined prior to commencing recruitment.\n\nRepeat SBRT will be permissible upon development of subsequent OPD lesions dependent on SBRT suitability and total progression lesion number at any one point remaining ≤ 5.","label":"SBRT and continued TKI therapy","type":"EXPERIMENTAL"},{"description":"Continuation on the same background TKI treatment as prior to trial entry","label":"Continued TKI therapy alone","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-06-30","type":"ESTIMATED"},"conditions":["NSCLC"],"enrollment":{"count":113,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"SBRT","otherNames":["Stereotactic body radiotherapy","SABR"],"type":"RADIATION"},{"name":"TKI","otherNames":["Tyrosine Kinase Inhibitor"],"type":"DRUG"}],"last_update":"2026-11-05","lead_sponsor":"Institute of Cancer Research, United Kingdom","official_title":"Targeted Therapy With or Without Dose Intensified Radiotherapy for Oligo-progressive Disease in Oncogene-addicted Lung Tumours","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2023-07-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression free survival","timeFrame":"Time from randomisation to the first of one of the above events or death. Assessed 8 weeks post-randomisation and 3-monthly thereafter (up to 24 months)"}],"references":[{"citation":"Lee J, Koom WS, Byun HK, Yang G, Kim MS, Park EJ, Ahn JB, Beom SH, Kim HS, Shin SJ, Kim K, Chang JS. Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2022 Jun;21(2):e78-e86. doi: 10.1016/j.clcc.2021.10.009. Epub 2021 Nov 18.","pmid":"34903471","type":"DERIVED"}],"start_date":{"date":"2017-11-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Stereotactic Body Radiotherapy for the Treatment of OPD","url":"https://clinicaltrials.gov/study/NCT03256981"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/halt-nct03256981"}